Adage Capital Partners’s Zevra Therapeutics ZVRA Stock Holding History

Adage Capital Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Hold	200,000	–	–	﹤0.01%	850
2026 Q1	$1.86M	Sell	200,000 -75,000	-27%	-$676K	﹤0.01%	845
2025 Q4	$2.46M	Sell	275,000 -1,950,000	-88%	-$18.4M	﹤0.01%	824
2025 Q3	$21.2M	Sell	2,225,000 -1,943,000	-47%	-$19.5M	0.03%	452
2025 Q2	$36.7M	Buy	4,168,000 +550,000	+15%	+$4.46M	0.06%	304
2025 Q1	$27.1M	Sell	3,618,000 -32,000	-0.9%	-$254K	0.05%	349
2024 Q4	$30.4M	Buy	3,650,000 +3,001,000	+462%	+$25.6M	0.05%	323
2024 Q3	$4.5M	Buy	+649,000	New	+$4.41M	0.01%	725

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners's ZVRA Position: Q2 2026 in Review

Adage Capital Partners held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 200,000 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Adage Capital Partners first reported a position in ZVRA in Q3 2024 and has held it in 8 quarters since. The position peaked at $36.7M in Q2 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Adage Capital Partners held 200,000 shares of Zevra Therapeutics worth $2.87M as of Q2 2026.
Adage Capital Partners left its Zevra Therapeutics share count unchanged in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #850 holding.
Adage Capital Partners first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 8 quarters since.
Adage Capital Partners's Zevra Therapeutics position peaked at $36.7M in Q2 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.